Celsus Therapeutics and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno ...

Although chloramphenicol continues to be the leading single cause of drug-induced aplastic anemia, little progress has been made in elucidating the mechanism of its toxic effect. The reversible ...

Chloramphenicol is a potent antibiotic used in humans for eye infections, typhoid and cholera, according to a StatPearls article in the National Library of Medicine.

Celsus Therapeutics Plc and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors ...

Celsus Therapeutics will acquire Volution Immuno Pharmaceuticals (VIP), creating a combined company focused on developing and commercializing treatments for orphan autoimmune and inflammatory ...

NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo ...

British drugmaker Celsus Therapeutics Plc's U.S.-listed shares plunged as much as 83 percent after the company's skin cream failed the main goal of a mid-stage study.

Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY).According to a SEC filing, Broadfin purchased around 3.5 ...

Chloramphenicol was given to 15 children who had no acute infectious disease at the Children's Convalescent Home, an institution for recuperating children in the suburbs of Washington, D. C.